Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 7;6(1):e2014028.
doi: 10.4084/MJHID.2014.028. eCollection 2014.

Tyrosine kinase inhibitors and pregnancy

Elisabetta Abruzzese  1 , Malgorzata Monika Trawinska  1 , Alessio Pio Perrotti  1 , Paolo De Fabritiis  1
Affiliations
Review

Tyrosine kinase inhibitors and pregnancy

Elisabetta Abruzzese et al. Mediterr J Hematol Infect Dis. .

Abstract

The management of patients with chronic myeloid leukemia (CML) during pregnancy has become recently a matter of continuous debate. The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of CML patients; in fact, patients diagnosed in chronic phase can reasonably expect many years of excellent disease control and good quality of life, as well as a normal life expectancy, including the necessity to address issues relating to fertility and pregnancy. Physicians are frequently being asked for advice regarding the need for, and/or the appropriateness of, stopping treatment in order to conceive. In this report, we will review the data published in terms of fertility, conception, pregnancy, pregnancy outcome and illness control for TKI treated CML patients, as well as how to manage a planned and/or unplanned pregnancy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

References

    1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myeloid leukemia in mice by the p210 bcr-abl gene of the Philadelphia chromosome. Science. 1990;247:824–30. doi: 10.1126/science.2406902. - DOI - PubMed
    1. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306:239–42. doi: 10.1038/306239a0. - DOI - PubMed
    1. Deininger MWN, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood. 1997;90(9):3691–3698. - PubMed
    1. Marley SB, Deininger MWN, Davidson RJ, Goldman JM, Gordon MY. The tyrosine kinase inhibitor STI571, like interpheron-a preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Experimental Hematology. 2000;28:551–557. doi: 10.1016/S0301-472X(00)00142-9. - DOI - PubMed
    1. Abruzzese E, Breccia M, Latagliata R. Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML) BioDrugs. 2013 Sep 17; [Epub ahead of print] - PubMed